Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197580 | 1.00 | PFKFB3 (0.73) | PFKFB3HDAC6CYP1A2CYP1A1CYP3A4 | |
| SCHEMBL29402512 | 1.00 | PFKFB3 (0.73) | PFKFB3HDAC6CYP1A2CYP1A1CYP3A4 | |
| SCHEMBL10309039 | 0.86 | PFKFB3 (0.81) | PFKFB3HDAC6CYP1A2CYP1B1LMNA | |
| SCHEMBL10275355 | 0.86 | PFKFB3 (0.81) | PFKFB3HDAC6CYP1A2CYP1B1LMNA | |
| SCHEMBL29351503 | 0.85 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A2CYP1A1CYP2D6 | |
| SCHEMBL29399327 | 0.85 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A2CYP1A1CYP2D6 | |
| SCHEMBL2702934 | 0.85 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A2CYP1A1CYP2D6 | |
| SCHEMBL16534534 | 0.85 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A2CYP1A1CYP2D6 | |
| SCHEMBL10309038 | 0.81 | PFKFB3 (0.56) | PFKFB3HDAC6CYP1A2CYP1A1CYP3A4 | |
| SCHEMBL10275589 | 0.81 | PFKFB3 (0.56) | PFKFB3HDAC6CYP1A2CYP1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230312728-A1 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220290241-A1 | PREDICTING EXTRAINTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER | 2022-09-15 | — | — | US | disclosed |
| WO-2022112439-A1 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISEASE | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2022-06-02 | — | — | WO | disclosed |
| US-20210079473-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING SEVERE CROHN'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| EP-2167058-B1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIV LOUISVILLE RES FOUND (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8088385-B2 | PFKB3 inhibitor for the treatment of a proliferative cancer | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | PFKFB3 4865/4885HDAC6 2064/4885CYP1A2 4505/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | PFKFB3 4865/4885HDAC6 2064/4885CYP1A2 4505/4885 |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | PFKFB3 1/4885HDAC6 910/4885CYP1A2 4666/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | PFKFB3 4878/4885HDAC6 2043/4885CYP1A2 3659/4885 |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | IAPP, APP, SLC2A3 | PFKFB3 27/4885HDAC6 4256/4885CYP1A2 2798/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | PFKFB3 4875/4885HDAC6 2530/4885CYP1A2 4360/4885 |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | TLL1, TSG101, DNASE1L3 | PFKFB3 4878/4885HDAC6 2043/4885CYP1A2 3659/4885 |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | PFKFB3 1/4885HDAC6 910/4885CYP1A2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.